As the healthy female donors had ~0.5% CD44+/CD24− cells, we collected these cells and analyzed exon 6 and exon 8 of the TP53 gene to check whether they harbored any of the breast cancer-associated mutations. This evidence concerns the gene TP53 and breast carcinoma.